Takeda Cambridge, Dimerix In Second GPCR Pact

Dimerix Bioscience Pty Ltd. has entered into a second research program with Takeda Cambridge Ltd., a UK based subsidiary of Takeda Pharmaceutical Co. This new program is in addition to the companies’ April 2010 research collaboration.

Dimerix is a preclinical stage company developing a pipeline of lead products with highly specific activity and reduced risk of off-target effects. Under the new agreement, Dimerix will continue to use its GPCR-HIT platform and G Protein-Coupled Receptors (GPCRs) expertise to form complexes to work with additional undisclosed Takeda targets.

Mark Carlton, president of Takeda Cambridge Ltd. said: “We are impressed by Dimerix’s achievements over the last 12 months and with the depth of information we have obtained by accessing the power of their GPCR-HIT platform. We have seen that the insights generated using GPCR-HIT provide us with an important extension to our GPCR drug discovery efforts. We are very pleased to be able to expand our efforts with Dimerix.”

Tim Grogan, chief executive officer of Dimerix, said: “We are very pleased with this further expansion of our relationship with Takeda Cambridge. The relevance of our GPCR-HIT platform to the drug discovery and development process and our insights into the formation of complexes between G Protein-Coupled Receptors have been recognized again through this partnership with Takeda Cambridge.”